Semaglutide Brands in India 2026
Every DCGI-Approved Brand · Prices · Manufacturers
12 manufacturers · 26+ brands · patent expired March 20, 2026 · updated April 2026
AT A GLANCE · 12 manufacturers · 26+ brands
TL;DR · India semaglutide market, April 2026
- Cheapest overall: Eris SUNDAE at ₹220 per shot (₹1,290/month vial format) — globally the lowest entry price for semaglutide.
- Cheapest prefilled pen: Alkem Semasize from ₹1,800/month.
- Only reusable pen in India: Zydus Semaglyn (also co-marketed by Lupin and Torrent) — cartridge-based, lets you titrate without replacing the device.
- Only oral (tablet) generic: Torrent Semalix — generic Rybelsus equivalent in 3 mg, 7 mg, 14 mg.
- Innovator pricing (post 48% cut): Novo Nordisk Ozempic ₹5,660/month · Wegovy ₹8,640/month. Still a premium, but carries the full global clinical trial data package.
- Different molecule: Eli Lilly Mounjaro (tirzepatide) ₹14,000–27,500/month. Superior average weight loss vs semaglutide; no Indian generic yet.
All brands below are DCGI-approved and Schedule H (prescription-only). GLP-1 Check does not endorse any brand. Check your eligibility in 5 minutes →
Price Comparison — All 12 Manufacturers
| Brand | Company | Est. Price | Format | Indication | Source |
|---|---|---|---|---|---|
| Noveltreat / Sematrinity | Sun Pharma | ₹750–2,000/mo | Prefilled pen | Obesity + T2D | Sun Pharma PR → |
| Obeda / Usema | Dr. Reddy's + USV | ₹4,200/mo | Prefilled pen | T2D | Pearce IP → |
| Semaglyn / Mashema / Alterme | Zydus (+ Lupin, Torrent) | ₹2,200–5,500/mo | Reusable pen | T2D + Obesity | Business Standard → |
| Semanext / Livarise | Lupin (via Zydus) | ₹2,200/mo | Reusable pen | T2D + Obesity | Pearce IP → |
| Semasize / Obesema / Hepaglide | Alkem Laboratories | ₹1,800–3,500/mo | Prefilled pen | T2D + Obesity | Outlook Business → |
| SUNDAE / Semanat / Semafull | Eris / Natco | ₹220/shotLowest price | Vial + Pen | T2D + Obesity | Business Today → |
| GLIPIQ | Glenmark | ₹325–440/week | Vial + Pen | T2D | Pearce IP → |
| Sembolic / Semalix | Torrent | TBC | Injectable + Oral | T2D + Obesity | Business Standard → |
| Semabest | MSN Laboratories | ₹3,990/mo | Prefilled pen | T2D | BioSpectrum India → |
| Samakind | Mankind | TBC | Pen | Multiple | Business Today → |
| Ozempic / Extensior / Rybelsus | Novo Nordisk (Extensior co-marketed by Abbott)Innovator | ₹5,660–9,100/mo | Pen (Ozempic/Extensior) + Tablet (Rybelsus) | T2D | Business Standard → |
| Wegovy / Poviztra | Novo Nordisk (Poviztra co-marketed by Emcure)Innovator | ₹3,999–16,400/mo | Prefilled pen | Obesity | Business Standard → |
| Different molecule — tirzepatide (GIP + GLP-1 dual agonist) | |||||
| MounjaroTirzepatide | Eli Lilly | ₹14,000–27,500/mo | KwikPen (2.5mg–15mg) · Vial | T2D + Obesity | Reuters → |
Ozempic / Extensior / Rybelsus
Novo Nordisk (Extensior co-marketed by Abbott)Innovator
₹5,660–9,100/mo
Novo Nordisk (Poviztra co-marketed by Emcure)Innovator
₹3,999–16,400/mo
Semaglutide brands: 20+ DCGI-approved generics plus Ozempic and Wegovy (Novo Nordisk). Mounjaro (tirzepatide) is listed separately — it is a different molecule and not a semaglutide generic. Prices indicative as of April 2026. Always verify with your pharmacist. GLP-1 Check does not endorse any brand.
Price is only half the question. Are you eligible?
Indian BMI thresholds differ from US/European cut-offs. Our free 5-minute triage uses ESI India guidelines to check if you qualify for semaglutide therapy.
CALCULATOR
Estimate Your Semaglutide Cost
Pick a brand and a treatment duration — this tool shows the monthly cost range and total spend, and what you'd save by switching to a cheaper DCGI-approved generic.
Estimate your cost
How much will semaglutide cost you per month and in total?
₹220/shot vial format · ₹1,290–1,750/month at typical titration. Pen device launched April 2026 at ₹4,000–4,500/month.
Monthly cost
₹1,290 – ₹1,750
Total over 6 months
₹7,740 – ₹10,500
Prices are indicative April 2026 and exclude consultation, titration period variation, and possible insurance coverage. Semaglutide is a Schedule H drug — a prescription is required. This tool is informational only, not medical or financial advice.
HEAD-TO-HEAD
Ozempic vs Wegovy vs Generics vs Mounjaro
Four options Indian patients actually choose between. Ozempic, Wegovy and the generics are all semaglutide. Mounjaro is tirzepatide — a different molecule with different trial data.
| Attribute | Ozempic (Novo) | Wegovy (Novo) | Generic semaglutide | Mounjaro (Lilly) — tirzepatide |
|---|---|---|---|---|
| Active molecule | Semaglutide | Semaglutide | Semaglutide | Tirzepatide |
| Receptor activity | GLP-1 | GLP-1 | GLP-1 | GIP + GLP-1 (dual agonist) |
| Primary indication | Type 2 diabetes | Chronic weight management | T2D &/or obesity (brand-dependent) | T2D + obesity |
| Max maintenance dose | 1.0 mg weekly (some up to 2.0 mg) | 2.4 mg weekly | 0.5–2.4 mg weekly | 15 mg weekly |
| Avg. weight loss at target dose (trial data) | ~6% | ~15% (STEP 1) | ~15% (same molecule) | ~21% (SURMOUNT) |
| CV risk reduction labelled | Yes (T2D + CVD) | Yes (SELECT — obesity + CVD) | Label inherits evidence; may not be explicit | Under study |
| Format | Prefilled FlexTouch pen | Prefilled pen | Vial, prefilled pen, reusable pen, oral tablet | Prefilled KwikPen + single-dose autoinjector |
| India price (May 2026) | ₹5,660–9,100/month | ₹5,660–16,400/month (Poviztra co-marketed: ₹3,999–8,999/month) | ₹220/shot · ₹750–5,500/month | ₹14,000–27,500/month |
| DCGI-approved | Yes (pre-2026) | Yes (2025–2026) | Yes — 9+ Indian manufacturers | Yes (March 2025) |
| Generic competition in India | n/a (innovator) | n/a (innovator) | Yes — this page lists them all | No — no Indian biosimilar yet |
Ozempic
Novo Nordisk · semaglutide
- Active molecule
- Semaglutide
- Receptor activity
- GLP-1
- Primary indication
- Type 2 diabetes
- Max maintenance dose
- 1.0 mg weekly (some up to 2.0 mg)
- Avg. weight loss at target dose (trial data)
- ~6%
- CV risk reduction labelled
- Yes (T2D + CVD)
- Format
- Prefilled FlexTouch pen
- India price (May 2026)
- ₹5,660–9,100/month
- DCGI-approved
- Yes (pre-2026)
- Generic competition in India
- n/a (innovator)
Wegovy
Novo Nordisk · semaglutide
- Active molecule
- Semaglutide
- Receptor activity
- GLP-1
- Primary indication
- Chronic weight management
- Max maintenance dose
- 2.4 mg weekly
- Avg. weight loss at target dose (trial data)
- ~15% (STEP 1)
- CV risk reduction labelled
- Yes (SELECT — obesity + CVD)
- Format
- Prefilled pen
- India price (May 2026)
- ₹5,660–16,400/month (Poviztra co-marketed: ₹3,999–8,999/month)
- DCGI-approved
- Yes (2025–2026)
- Generic competition in India
- n/a (innovator)
Generic semaglutide
9+ Indian manufacturers
- Active molecule
- Semaglutide
- Receptor activity
- GLP-1
- Primary indication
- T2D &/or obesity (brand-dependent)
- Max maintenance dose
- 0.5–2.4 mg weekly
- Avg. weight loss at target dose (trial data)
- ~15% (same molecule)
- CV risk reduction labelled
- Label inherits evidence; may not be explicit
- Format
- Vial, prefilled pen, reusable pen, oral tablet
- India price (May 2026)
- ₹220/shot · ₹750–5,500/month
- DCGI-approved
- Yes — 9+ Indian manufacturers
- Generic competition in India
- Yes — this page lists them all
Mounjaro
Eli Lilly · tirzepatide
- Active molecule
- Tirzepatide
- Receptor activity
- GIP + GLP-1 (dual agonist)
- Primary indication
- T2D + obesity
- Max maintenance dose
- 15 mg weekly
- Avg. weight loss at target dose (trial data)
- ~21% (SURMOUNT)
- CV risk reduction labelled
- Under study
- Format
- Prefilled KwikPen + single-dose autoinjector
- India price (May 2026)
- ₹14,000–27,500/month
- DCGI-approved
- Yes (March 2025)
- Generic competition in India
- No — no Indian biosimilar yet
Weight-loss percentages are trial averages at target dose — individual response varies. Sources: STEP 1, SELECT, SURMOUNT trials (see Knowledge Center). Prices as of April 2026.
ALL 12 MANUFACTURERS
Manufacturer-by-Manufacturer Guide
Sun Pharma
India's largest pharma — two brands covering obesity and T2D
₹750–2,000/mo
Format: Noveltreat: concealed needle prefilled pen · Sematrinity: multi-dose pen
Concealed needle design reduces injection fear. Phase III India trial completed. Patient support programme alongside both brands.
Dr. Reddy's + USV
First DCGI approval — also licensed to USV as Usema
₹4,200/mo (Obeda) · USV TBC
Format: Prefilled disposable pen — 4 weekly doses per pen · 2mg and 4mg strengths
First Indian company to receive DCGI approval. SemaKare digital support system provides injection training and tele-support. Plans to launch in 87 countries.
Zydus Lifesciences
Only reusable pen in India — licensed to Lupin and Torrent
₹2,200/mo (diabetes) · ₹3,500–5,500/mo (obesity)
Format: Reusable multi-dose pen — 15mg/3ml cartridge. Replace cartridges, not the device.
Only reusable pen on market — allows dose adjustment during titration without changing device. Also licensed to Lupin (Semanext, Livarise) and Torrent.
Lupin (via Zydus)
Co-marketed Zydus semaglutide — metro and Tier 2 specialist reach
₹2,200/mo
Format: Reusable multi-dose pen (Zydus device) — identical product to Semaglyn/Mashema/Alterme
Lupin holds semi-exclusive rights to co-market Zydus semaglutide under its own brands. Same molecule, same device. Lupin's value is its commercial reach in cardiology and endocrinology specialist channels.
Alkem Laboratories
Lowest-priced prefilled pen — three brands, three indications
₹1,800/mo (₹450/week)
Format: Disposable prefilled pen + reusable cartridge pen option · 0.25mg–2.4mg strengths
Lowest priced prefilled pen in India. Three separate brands cover different indications — Hepaglide targets the emerging MASH/fatty liver indication, the only brand to do so. Phase III India trial completed. Extensive Tier 2/3 distribution.
Eris Lifesciences / Natco Pharma
Globally lowest entry price — vial format for hospitals and clinics
₹220/shot · ₹1,290–1,750/mo (vial) · ₹4,000–4,500/mo (pen)
Format: Multi-dose vial (available now) · Pen device expected April 2026
At ₹220 per shot, SUNDAE has the lowest entry price of any semaglutide product in India. Vial format suited to hospital and clinic settings where nurses administer doses. Pen device launching April 2026.
Glenmark Pharmaceuticals
Vial and pen formats — Sankalp patient support programme
₹325–440/week (vial)
Format: Multi-dose vial (₹325–440/week) + prefilled pen · 2mg/1.5ml, 4mg/3ml, 8mg/3ml
Glenmark's Sankalp programme supports patient initiation and adherence. Vial format enables lowest-cost flexible dosing. Both vial and pen received DCGI approval.
Torrent Pharmaceuticals
Only company with oral semaglutide — injectable + tablet both available
TBC
Format: Injectable (via Zydus) + oral tablets (3mg, 7mg, 14mg — generic Rybelsus equivalent)
Only Indian company with oral semaglutide at launch — a generic equivalent of Rybelsus in all three dosages. Also has injectable via Zydus licensing agreement.
MSN Laboratories
First integrated made-in-India semaglutide — backward-integrated API + pen device
₹3,990/mo
Format: Prefilled pen · made-in-India device
MSN Laboratories is the first Indian manufacturer to vertically integrate semaglutide — both the USDMF-grade API and the pen device are produced in-house. This reduces dependence on imported components and supports supply stability at scale. Phase III bioequivalence study showed comparable HbA1c, fasting glucose, post-prandial glucose, and weight outcomes vs the reference innovator.
Mankind Pharma
Unmatched Tier 2/3 city distribution across India
TBC
Format: Pen · dose strengths TBC
Mankind's key advantage is its Tier 2/3 city distribution — the deepest of any Indian pharma company. Samakind may be the first semaglutide brand to meaningfully reach patients outside metro India.
Novo Nordisk
Semaglutide innovator — Ozempic, Wegovy, Rybelsus + Abbott/Emcure co-marketed brands
₹3,999–16,400/mo (post April 2026 price cut)
Format: Ozempic / Extensior: prefilled FlexTouch pen (0.25mg, 0.5mg, 1mg weekly) · Wegovy / Poviztra: prefilled pen (0.25mg–2.4mg weekly) · Rybelsus: oral tablet (3mg, 7mg, 14mg daily)
Novo Nordisk invented semaglutide — the original molecule behind every generic on this page. In April 2026, Novo Nordisk cut Indian prices ~48%, bringing Ozempic to ₹5,660/month and Wegovy starter dose to ₹5,660/month. Two co-marketed brands extend reach: Extensior (Abbott India, T2D, February 2026 launch) deepens specialist endocrinology distribution; Poviztra (Emcure, obesity, December 2025) targets tier-2/3 cities at ₹3,999–8,999/month. Wegovy uniquely carries SELECT-trial cardiovascular risk reduction data, a label most Indian generics do not yet carry.
Tirzepatide is related to but distinct from semaglutide. It activates two receptor types (GIP + GLP-1) vs semaglutide's one. Clinical trials show superior average weight loss but it carries a significantly higher price point.
Eli Lilly
Tirzepatide — dual GIP+GLP-1 receptor agonist with superior weight loss data
₹14,000–27,500/mo
Format: Prefilled KwikPen (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg weekly) · single-dose autoinjector
Tirzepatide is a different molecule — it activates both GIP and GLP-1 receptors simultaneously, unlike semaglutide which is GLP-1 only. SURMOUNT trials demonstrated ~22% body weight reduction vs ~15% for semaglutide at highest doses. DCGI approved Mounjaro in March 2025. Currently priced at ₹14,000–27,500/month — premium to all semaglutide options. No Indian generic equivalent exists yet.
HOW YOU'RE DOSED
Semaglutide Dose Schedule & Titration
Semaglutide is titrated slowly over ~16 weeks to let the body adapt. The schedule is the same across all DCGI-approved Indian generics and the innovator brands — the molecule and pharmacokinetics are identical.
Why the slow ramp?
GI side effects (nausea, vomiting, diarrhoea) are dose-dependent. Most patients who discontinue semaglutide stop because of side effects, not because it doesn't work. A slow titration keeps them tolerable and lets most people reach the maintenance dose.
What if you stop?
Weight regain after stopping GLP-1 therapy is faster than after lifestyle-only programmes — typically ~two-thirds of lost weight returns within a year. Read the evidence →
Schedule shown is the standard obesity titration to the 2.4 mg maintenance dose. For type 2 diabetes, most patients stop at 0.5–1.0 mg. Always titrate under medical supervision — this is not medical advice.
WHAT TO EXPECT
Semaglutide Side Effects
Side effects are identical across all DCGI-approved Indian semaglutide generics — the molecule is the same as Ozempic/Wegovy. Device quality and cold-chain handling can vary between brands.
Very common (≥10% of patients)
- Nausea — peaks during titration, typically subsides within 4–8 weeks at a stable dose
- Vomiting, diarrhoea, constipation
- Abdominal pain or discomfort
- Reduced appetite (this is the therapeutic effect, not an adverse effect)
Less common but serious — stop and see a doctor
- Severe, persistent abdominal pain radiating to the back → possible pancreatitis
- Right upper abdomen pain, fever, yellowing → possible gallstones / gallbladder disease
- Persistent neck lump, hoarseness, difficulty swallowing → evaluate thyroid
- Rapid heartbeat, severe dehydration from vomiting
- Hypoglycaemia when semaglutide is combined with insulin or sulfonylureas
What the Indian data shows: a 2025 study of Indian patients found GI side effects are the leading cause of discontinuation, peaking during dose escalation. Read the full study → For a patient-friendly walkthrough of managing side effects at home, see our India side-effects guide →.
This section is informational only and does not replace medical advice. Report any severe or persistent symptom to your prescriber.
SAFETY
Who Should Not Take Semaglutide
Not everyone is a candidate. These rules apply to all semaglutide brands — generic and innovator alike — because they stem from the molecule, not the formulation.
Absolute — never prescribed
Medullary thyroid carcinoma (MTC) history
Personal or family history of MTC, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). All GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumours based on rodent data.
Known hypersensitivity
Previous serious allergic reaction (anaphylaxis, angioedema) to semaglutide or any pen/vial excipient.
Pregnancy & breastfeeding
Not approved for pregnant or breastfeeding women. Discontinue at least two months before planned pregnancy.
Caution — discuss carefully with your prescriber
Active or prior pancreatitis
Post-marketing reports of acute pancreatitis. Discuss carefully with your doctor; alternative therapies may be preferred.
Severe gastrointestinal disease / gastroparesis
Semaglutide slows gastric emptying. If you already have gastroparesis or severe chronic GI disease, this can worsen symptoms.
Active proliferative diabetic retinopathy
Rapid glucose lowering has been associated with short-term worsening of diabetic retinopathy. An ophthalmology review is advisable before starting.
Severe renal or hepatic impairment
Limited clinical data in end-stage renal disease or severe hepatic impairment. Dose decisions are case-by-case.
Type 1 diabetes
Semaglutide is approved for type 2 diabetes and obesity — not for type 1 diabetes. It does not replace insulin.
Active eating disorder
Semaglutide can worsen restrictive eating disorders. Screen before prescribing to patients pursuing weight loss.
Age under 18
Paediatric use is approved only for specific semaglutide indications in the US/EU; Indian approvals vary by brand. Not routinely prescribed to minors.
Not sure where you fit? Our free triage uses Indian clinical guidelines (ESI India, ICMR-INDIAB) to screen for these flags and suggest whether semaglutide is appropriate — or whether you should explore alternatives first. Start the 5-minute assessment →
REGULATORY TIMELINE
India Regulatory Timeline
Sources linked on each item. Updated as news breaks.
April 18, 2026
Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs — state regulators directed to enforce
Medical Dialogues →March 24, 2026
CDSCO tightens checks on generic semaglutide — bans promotional activity, intensifies pharmacy surveillance
Business Standard →March 21, 2026
Patent expiry Day 1 — 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions
CNBC →March 17, 2026
Zydus–Lupin and Zydus–Torrent licensing agreements announced ahead of patent expiry
Pearce IP →February 2026
Natco Pharma receives CDSCO approval for generic semaglutide — Eris Lifesciences to commercialise
Fierce Pharma →December 2025
Sun Pharma receives first DCGI approval for generic semaglutide in India — Noveltreat and Sematrinity
Sun Pharma PR →REGULATORY FRAMEWORK
CDSCO Standards & Approval
Requirements in India
India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator — equivalent to the US FDA. Every semaglutide brand on this page is DCGI-approved. Here's what that means for patients.
Schedule H Prescription Drug
Semaglutide is classified as Schedule H in India — meaning it can only be dispensed against a valid prescription from a registered medical practitioner. It cannot be purchased over the counter.
Prescription must be from an endocrinologist or internal medicine specialist. Cardiologists may prescribe for cardiovascular indications.
CDSCO / Business Standard, March 2026 →Phase III Trial Requirement
DCGI requires Indian manufacturers to submit Phase III clinical trial data from Indian patients before approval — not just bioequivalence data used for standard generics.
Sun Pharma's Noveltreat and Alkem's brands both conducted India-specific Phase III trials. This is a higher standard than most generic drug approvals.
Medical Dialogues / DCGI Approval Notice →CDSCO Approved BMI Thresholds
DCGI has approved semaglutide for obesity in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, T2D, dyslipidaemia, or sleep apnea).
Note: Indian clinical guidelines (ESI, ICMR) recommend lower thresholds of BMI ≥25 for Indians. Our triage tool uses Indian-adjusted criteria.
DCGI Approval — Medical Dialogues (citing CDSCO approval document) →Intensified Regulatory Surveillance
Following the March 2026 generic wave, CDSCO announced intensified surveillance against unauthorised sale and unethical marketing. Non-compliance leads to licence cancellation.
CDSCO has explicitly barred all manufacturers from promotional activities around semaglutide. This is why you will not see TV or print advertising for these brands.
Business Standard, March 24 2026 →DCGI-Approved Brands on This Page
All brands listed on GLP-1 Check have received formal approval from the Drugs Controller General of India (DCGI). We do not list unapproved or unverified products.
Beware of unapproved products
The explosion of cheap semaglutide has also created a market for counterfeit and substandard products. Only purchase from a licensed pharmacy with a valid prescription. If a price seems too low (under ₹500/month for a full dose), verify the brand's DCGI approval status before purchasing. CDSCO maintains a list of approved drugs at cdsco.gov.in →
FREQUENTLY ASKED
Questions About Indian Semaglutide Brands
Which is the cheapest semaglutide brand in India?
As of May 2026, Eris SUNDAE is the globally lowest-priced semaglutide at ₹220 per shot (vial format, T2D + obesity). For prefilled pens, Sun Pharma's Noveltreat (obesity) / Sematrinity (T2D) starts at ₹750/month — the cheapest pen on the market. Glenmark GLIPIQ vials start at ₹325/week (~₹1,300/month). Alkem Semasize starts at ₹1,800/month with sister brands Obesema (obesity) and Hepaglide (MASH positioning). Zydus Semaglyn reusable pen starts at ₹2,200/month. MSN Semabest at ₹3,990/month flat for T2D. Innovator Ozempic now at ₹5,660/month starter dose post April 2026 price cut.
How many semaglutide brands are available in India in 2026?
As of May 2026, at least 10 Indian generic manufacturers have launched semaglutide under 20+ brand names. The major generics are Noveltreat/Sematrinity (Sun Pharma), Obeda/Usema (Dr Reddy's + USV), Semaglyn/Mashema/Alterme (Zydus), Semanext/Livarise (Lupin via Zydus), Semasize/Obesema/Hepaglide (Alkem), GLIPIQ (Glenmark), Sembolic/Semalix (Torrent — injectable + oral), Semabest (MSN Labs — first integrated made-in-India semaglutide, April 2026 launch), SUNDAE/Semanat/Semafull (Eris/Natco), and Samakind (Mankind). Additionally, Novo Nordisk (the semaglutide innovator) sells Ozempic, Wegovy, Rybelsus, plus Abbott-co-marketed Extensior and Emcure-co-marketed Poviztra in India; Eli Lilly sells Mounjaro (tirzepatide, a related but distinct molecule). Total: 12 manufacturers, 25+ brands. More than 50 brand names from 40+ manufacturers expected by end of 2026.
Is Noveltreat the same as Wegovy?
Noveltreat contains the same active ingredient as Wegovy — semaglutide at 2.4mg for obesity. It is manufactured by Sun Pharma in India and approved by DCGI after a Phase III trial conducted in India.
Are all generic semaglutide brands equally effective?
All DCGI-approved generics contain the same active molecule. Approval requires bioequivalence to the reference product. Clinical efficacy should be equivalent, though device quality and cold chain handling can vary between brands.
Do I need a prescription for semaglutide in India?
Yes. Semaglutide is a Schedule H prescription drug. A valid prescription from a registered doctor is required. Self-medication is unsafe due to contraindications and the need for supervised dose escalation.
What is the difference between semaglutide for diabetes vs obesity?
The molecule is identical. Diabetes doses go up to 1mg weekly (Ozempic equivalent). Obesity treatment uses 2.4mg weekly maintenance (Wegovy equivalent). Some Indian brands are approved for both, others for one indication only.
Which brand is best for someone with both diabetes and obesity?
Brands approved for BOTH T2D and obesity: Semaglyn / Mashema / Alterme (Zydus), Semanext / Livarise (Lupin), Semasize / Obesema / Hepaglide (Alkem), SUNDAE / Semanat / Semafull (Eris/Natco), Sembolic / Semalix (Torrent — including oral tablets), and Samakind (Mankind). Sun Pharma uses dual brands: Noveltreat for obesity, Sematrinity for T2D (same molecule, separate DCGI labels). Single-indication generics: Obeda / Usema (Dr Reddy's, T2D), Semabest (MSN, T2D), GLIPIQ (Glenmark, T2D). Innovator brands: Ozempic for T2D, Wegovy for obesity. Mounjaro covers both. Our triage tool helps identify which indication applies to your case.
Is the vial format as effective as the pen?
Yes — the semaglutide molecule is the same. The difference is administration method. Vials require drawing the medication with a syringe. Pens are pre-filled and easier for self-injection. Both deliver the same drug.
Will semaglutide prices fall further in India?
Likely. Sun Pharma's Noveltreat is already at ₹750/month — below the ₹800–1,000 floor analysts forecasted in early 2026. Continued price competition is expected as additional manufacturers enter the market through 2026-2027. Innovator brands (Ozempic, Wegovy) cut prices ~36-48% in April 2026; further generic-pressure-driven cuts are plausible.
Can I switch between brands?
In principle yes, but always consult your doctor before switching. Dose calibration may differ between formats (vial vs pen). Your doctor should supervise any brand change.
Where can I buy semaglutide in India?
Semaglutide is a Schedule H drug — available through licensed retail and online prescription pharmacies and hospital pharmacies across India with a doctor’s prescription. Always buy from a licensed pharmacy to avoid counterfeit products; never use sources that dispense without verifying a prescription. The fastest first step: take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Which doctors can prescribe semaglutide in India?
CDSCO has approved semaglutide for prescription by endocrinologists and internal medicine specialists for diabetes and obesity indications. Cardiologists may prescribe for cardiovascular risk reduction indications. General physicians (GPs) are not currently authorised to prescribe semaglutide, though this may change as the market evolves.
How do I verify a semaglutide brand is DCGI-approved?
Visit cdsco.gov.in and search the approved new drugs database. All legitimate Indian generic semaglutide brands will have a DCGI approval number. You can also ask your pharmacist to show you the drug licence for the product. If in doubt, stick to well-known brands from established manufacturers.
Is it legal to buy semaglutide without a prescription in India?
No. Semaglutide is a Schedule H drug in India, which means it is illegal to sell or dispense it without a valid prescription from a registered medical practitioner. Online pharmacies selling semaglutide without a prescription are operating unlawfully. Always consult a doctor before starting treatment.
NOT SURE WHICH APPLIES TO YOU?
Check your eligibility in 5 minutes
Our triage tool determines if you are a candidate for GLP-1 therapy based on Indian clinical guidelines — free and anonymous.
Start the Assessment →